glp 1 in europe Advances GLP-1 receptor agonists delivery systems for obesity and diabetes GLP-1 Drugs Market Size to

As its use has expanded dramatically, particularly among individuals of reproductive age seeking weight loss, questions have emerged about potential effects on fertility

Moreover, patients with NASH, particularly those with advanced metabolic risk factors like hypertension or type 2 diabetes, face a higher risk of adverse cardiovascular events and increased morbidity and mortality

(2025b)

GLP-1 medications slow gastric emptying and reduce the rate at which the digestive system moves food through the intestines

In todays PAAD we will review an original article by Pai et al

Understanding the weight loss curve Weight loss on tirzepatide does not follow a straight line